Released Feb 27, 2012, after the close
10-K filed Feb 27, 2012, 58 days after period end · 0001144204-12-011082
Q4 2011 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.36M$2.36M derivedno prior Q4 2010 on file+108.7% vs Q3 2011
Net Income-$8.91M-$8.91M derivedno prior Q4 2010 on fileN/M vs Q3 2011
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$294,000—
Operating Incomederived-$8,858,000—
Operating Cash Flowderived-$6,612,000N/M
Free Cash Flowderived-$7,316,000N/M
Margins · derived
Gross margin12.4%
Operating margin-375.0%
Net margin-377.3%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2011dderived from reported figures | Q4 2010dderived from reported figures |
|---|---|---|
| Revenue | $2.36M | — |
| Net Income | -$8.91M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR